Faculty

Anne Andrews

Associate Professor of Molecular Toxicology
201 Life Sciences Building
Telephone: 814-865-2970
FAX: 814-863-5319
Email: ama11@psu.edu
Website: http://www.brain.psu.edu/

Research Focus

Andrews group research is centered on the chemistry of the serotonin neurotransmitter system. Our primary goal is to understand the role of serotonin in complex behavior, the etiology and treatment of depression and anxiety disorders, and aging. Genetically engineered mice, and drugs and neurotoxins are used to probe normal behavior and disease processes. Neurochemistry in these systems is investigated using bioanalytical techniques including carbon fiber microelectrode voltammetry and microdialysis coupled to high performance liquid chromatography with electrochemical detection. Additionally, autoradiography, immunocytochemistry, RT-qPCR and ELISA are used to study neuroadaptive changes in neuronal architectures, the expression of key proteins such as brain-derived neurotrophic factor and adult neurogenesis. Neurotransmitter-functionalized self-assembled monolayer “neurochips” have recently been designed for the development in vivo nanobiosensors and functionally-directed proteomics.

Publications

  1. The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 2'-NH2-MPTP. A. L. Numis, E. L. Unger, D. L. Sheridan, A. C. Chisnell and A. M. Andrews, Molecular Pharmacology, 66:718-727 (2004).
  2. Late onset loss of hippocampal 5-HT and NE is accompanied by an increase in BDNF protein expression in mice co-expressing mutant APP and PS1. M. E. Szapacs, A. L. Numis and A. M. Andrews, Neurobiology of Disease 16:572-580 (2004).
  3. Exploring the relationship between serotonin and brain-derived neurotrophic factor: Analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. M. E. Szapacs, T. A. Mathews, L. Tessarollo, W. E. Lyons, L. A. Mamounas and Error! Contact not defined., Journal of Neuroscience Methods 140:81-92 (2004).
  4. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. T. A. Mathews, D. E. Fedele, F. M. Coppelli, A. L. Avila, D. L. Murphy and A. M. Andrews, Journal of Neuroscience Methods 140:169-181 (2004).
  5. Chronoamperometry detects differential changes in synaptosomal uptake in serotonin transporter knockout mice. X. A. Perez and A. M. Andrews, Analytical Chemistry 77:818-826 (2005).
  6. Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. D.-K. Kim, T. J. Tolliver, S. J. Huang, B. J. Martin, A. M. Andrews, C. Wichems, A. Holmes, K.-P. Lesch, D. L. Murphy, Neuropharmacology, 49:798-810 (2005).
  7. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human -synuclein in mice. E. L. Unger, D. Eve, X. A. Perez, D. K. Reichenbach, Y. Xu, M. K. Lee and A. M. Andrews, Neurobiology of Disease, 21:431-443 (2006).
  8. The neurotoxin 2'-NH2-MPTP degenerates serotonin axons and evokes increases in hippocampal BDNF. B. A. Luellen, M. E. Szapacs, C. K. Materese and A. M. Andrews, Neuropharmacology, 50:297-308 (2006).
  9. Filtration disrupts synaptosomal membranes during radiochemical assay of serotonin uptake: Comparison with chronoamperometry in SERT knockout mice. X. A. Perez, L. E. Bianco and A. M. Andrews, Journal of Neuroscience Methods, 154:245-255 (2006).
  10. Radical-induced degradation of liposome-encapsulated microtubules as a model of axonal damage due to oxidative stress. A. E. Counterman, T. G. D’Onofrio, A. M. Andrews and P. S. Weiss, Proceedings of the National Academy of Sciences, USA, 103:5262-5266 (2006).
  11. MDMA-induced dopamine and serotonin release does not stimulate locomotor activity in SERT knockout mice: importance of 5-HT1B receptors. T. A. Mathews, E. L. Unger, D. E. Fedele, K.-P. Lesch, D. L. Murphy and A. M. Andrews, in Monitoring Molecules in Neuroscience. Proceedings of the 11th International Conference on In Vivo Methods. G. Di Chiara, E. Carboni, V. Valentini, E. Acquas, V. Bassareo and C. Cadoni eds., University of Cagliari, Cagliari, Italy (2006).
  12. Microcontact insertion printing. T. J. Mullen, C. Srinivasan, J. N. Hohman, S. D. Gillmor, M. J. Shuster, M. W. Horn, A. M. Andrews and P. S. Weiss, Applied Physics Letters, 90:063114/1-3 (2007).
  13. Determining serotonin and dopamine uptake rates using high-speed chronoamperometry. X. A. Perez, A. J. Bressler and A. M. Andrews, in Electrochemical Methods for Neuroscience. A. C. Michael and L. A. Borland, eds., CRC Press LLC, Boca Raton, FL, 103-124 (2007).
  14. Selecting and driving monolayer structures through tailored intermolecular interactions. T. J. Mullen, A. A. Dameron, A. M. Andrews and P. S. Weiss, Aldrichimica Acta, 40:21-31 (2007).
  15. Reduced BDNF is associated with a loss of serotonergic innervation in the hippocampus of aging mice. B. A. Luellen, L. E. Bianco, L. M. Schneider and A. M. Andrews, Genes, Brain and Behavior, in press.
  16. Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype. B. P. Guiard, D. P. David, T. Deltheil, J. –P. Guilloux, F. Chenu, E. Le Maître, T. Renoir, I. Leroux-Nicollet, P. Sokoloff, V. Arango, Y. Liu, M. Underwook, L. Lanfumey, M. Hamon, A. M. Andrews, R. Hen and A. M. Gardier, International Journal of Neurospychopharmacology, in press.
  17. A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. M. A. Fox, A. M. Andrews, J. R. Wendland, K. –P. Lesch, A. Holmes and D. L. Murphy, Psychopharmacology, in press.

 

 

 

 

 

DNA double helix